The ROC curves illustrated that a CD3+ percentage ≤ 63, a CD4+ percentage ≤ 38, a CD8+ percentage ≤ 18, and a CD20+ percentage ≤ 21 were the optimal cutoffs to identify NHL patients. This evidence concerns the gene CD4 and non-Hodgkin lymphoma.